AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25793707 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sodium valproate
Number of subjects: 72
Study 25793707 — intervention group
Group type: COMPARATOR
Intervention: 16 mg dexamethasone
Number of subjects: 72
Study 25793707 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sodium valproate (patients with aura)
Number of subjects: 72
Study 25793707 — intervention group
Group type: COMPARATOR
Intervention: 16 mg dexamethasone (patients with aura)
Number of subjects: 72
Study 23715256 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Static Stretching (PSS, N=11)
Number of subjects: 38
Study 23715256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hold-relax (HR, N=9)
Number of subjects: 38
Study 23715256 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretching (AIS, N=9)
Number of subjects: 38
Study 21341959 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' Matter! Program (PMP) intervention
Number of subjects: 339
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: Any X-ray examination of the mother during pregnancy
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray exposure during the first trimester
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray exposure during the third trimester
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray exposure during the second trimester
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: Any X-rays of the abdomen, pelvis, chest, or back
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: Other X-ray exposures (primarily dental X-rays)
Number of subjects: 638
Study 19293315 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester exposure and embryonal rhabdomyosarcoma
Number of subjects: 638
Study 17476567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 16
Study 17476567 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion (control)
Number of subjects: 16
Study 17476567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion during hyperglycaemia
Number of subjects: 16
Study 15221621 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting
Number of subjects: 120
Study 15221621 — intervention group
Group type: COMPARATOR
Intervention: Proximal steroid injections (betamethasone)
Number of subjects: 120
Study 15221621 — intervention group
Group type: COMPARATOR
Intervention: Distal steroid injections (betamethasone)
Number of subjects: 120
Study 12193270 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-chemically activated water (ECA) at pH 7.0
Number of subjects: 60
Study 12193270 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-chemically activated water (ECA) at pH 9.0
Number of subjects: 60
Study 12193270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl) 3.5%
Number of subjects: 60
Study 12193270 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study 9330411 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation plus surgery
Number of subjects: 0
Study 9330411 — intervention group
Group type: COMPARATOR
Intervention: Surgery or radiation alone
Number of subjects: 0
Study 8502438 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 108
Study 8502438 — intervention group
Group type: COMPARATOR
Intervention: Placebo control intervention (mimicking therapeutic touch)
Number of subjects: 108
Study 8502438 — intervention group
Group type: COMPARATOR
Intervention: Narcotic analgesic (standard intervention)
Number of subjects: 108
Study 3545642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion into the duodenum
Number of subjects: 0
Study 3545642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion into the ileum
Number of subjects: 0
Study 3545642 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of corn oil to a meal of mashed potato
Number of subjects: 0
Study 3545642 — intervention group
Group type: COMPARATOR
Intervention: Fat-containing meal
Number of subjects: 0
Study 29222541 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 0
Study 29222541 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 27000249 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 27000249 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (SC IFNB‐1a) 44 μg three times weekly
Number of subjects: 0
Study 25783198 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose multislice computed tomography (MSCT) screening
Number of subjects: 0
Study 23985210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 60
Study 23985210 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine therapy)
Number of subjects: 60
Study 21875633 — intervention group
Group type: EXPERIMENTAL
Intervention: mpHBV-Hib
Number of subjects: 543
Study 21875633 — intervention group
Group type: COMPARATOR
Intervention: Comvax™ (control)
Number of subjects: 543
Study 19289636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (n=52)
Number of subjects: 209
Study 19289636 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n=54)
Number of subjects: 209
Study 19289636 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance plus aerobic training (n=53)
Number of subjects: 209
Study 19289636 — intervention group
Group type: COMPARATOR
Intervention: No training (control group, n=50)
Number of subjects: 209
Study 19289636 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (after 1 month)
Number of subjects: 209
Study 17190530 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0
Study 17190530 — intervention group
Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 0
Study 17190530 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 0
Study 15526804 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone combination 50/500mcg bid
Number of subjects: 719
Study 15526804 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 719
Study 11212999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (50 microg every 6 h)
Number of subjects: 167
Study 11212999 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (50 microg every 6 h)
Number of subjects: 167
Study 11212999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 167
Study 11212999 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 167
Study 9043898 — intervention group
Group type: EXPERIMENTAL
Intervention: Humegon (FSH/LH ratio 1:1) via subcutaneous (s.c.) administration
Number of subjects: 18
Study 9043898 — intervention group
Group type: COMPARATOR
Intervention: Humegon (FSH/LH ratio 1:1) via intramuscular (i.m.) administration
Number of subjects: 18
Study 9043898 — intervention group
Group type: EXPERIMENTAL
Intervention: Normegon (FSH/LH ratio 3:1) via subcutaneous (s.c.) administration
Number of subjects: 18
Study 9043898 — intervention group
Group type: COMPARATOR
Intervention: Normegon (FSH/LH ratio 3:1) via intramuscular (i.m.) administration
Number of subjects: 18
Study 9043898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (Humegon and Normegon)
Number of subjects: 18
Study 7779855 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (murine anti-interleukin-2 receptor monoclonal antibody)
Number of subjects: 0
Study 7779855 — intervention group
Group type: COMPARATOR
Intervention: Murine monoclonal CD3 antibody
Number of subjects: 0
Study 7779855 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 treatment
Number of subjects: 0
Study 7779855 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from rejecting grafts
Number of subjects: 0
Study 7779855 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from patients without rejection
Number of subjects: 0
Study 7779855 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy material from rejecting grafts
Number of subjects: 0
Study 2245613 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction (Trach Care Closed Suction System)
Number of subjects: 84
Study 2245613 — intervention group
Group type: COMPARATOR
Intervention: Open suction method
Number of subjects: 84
Study 668932 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.9-mm vacuum system
Number of subjects: 0
Study 668932 — intervention group
Group type: COMPARATOR
Intervention: 12-mm vacuum system
Number of subjects: 0
Study 31422134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 202
Study 31422134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 31322086 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium plus standard antianginal and antiarrhythmic therapy for 2 months
Number of subjects: 147
Study 31322086 — intervention group
Group type: COMPARATOR
Intervention: Standard antianginal and antiarrhythmic therapy only
Number of subjects: 147
Study 28141942 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse breech extraction approach
Number of subjects: 192
Study 28141942 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 192
Study 25455433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard metatarsal pads (n=6, thermoplastic, ShoreA65)
Number of subjects: 12
Study 25455433 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft metatarsal pads (n=6, latex foam, Shore A11)
Number of subjects: 12
Study 25455433 — intervention group
Group type: COMPARATOR
Intervention: Control test (auditory sensations)
Number of subjects: 12
Study 26591621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free, alcohol-free mouthwash containing 0.075% CPC
Number of subjects: 120
Study 26591621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free, alcohol-free mouthwash containing 0.07% CPC
Number of subjects: 120
Study 26591621 — intervention group
Group type: COMPARATOR
Intervention: Non-antibacterial mouthwash
Number of subjects: 120
Study 23122974 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg loading dose followed by 30 μg/kg/min infusion)
Number of subjects: 56
Study 23122974 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 56
Study 21073744 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group tutorials
Number of subjects: 107
Study 21073744 — intervention group
Group type: COMPARATOR
Intervention: Interactive seminars
Number of subjects: 107
Study 18186737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured luting cement (RelyX ARC; 3M ESPE)
Number of subjects: 40
Study 18186737 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured luting cement (RelyX Veneer; 3M ESPE)
Number of subjects: 40
Study 18186737 — intervention group
Group type: COMPARATOR
Intervention: Both cement types
Number of subjects: 40
Study 17023237 — intervention group
Group type: COMPARATOR
Intervention: Electromechanical gait trainer (EGT)
Number of subjects: 50
Study 17023237 — intervention group
Group type: COMPARATOR
Intervention: Electromechanical gait trainer with functional electric stimulation (EGT‐FES)
Number of subjects: 50
Study 17023237 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 50
Study 12741866 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic shoe insoles (600 gauss)
Number of subjects: 14
Study 12741866 — intervention group
Group type: COMPARATOR
Intervention: Magnetic shoe insoles (125 gauss)
Number of subjects: 14
Study 12741866 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐yd dash performance
Number of subjects: 14
Study 11062355 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate
Number of subjects: 100
Study 11062355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8990429 — intervention group
Group type: EXPERIMENTAL
Intervention: One-layer closure
Number of subjects: 164
Study 8990429 — intervention group
Group type: COMPARATOR
Intervention: Two-layer closure
Number of subjects: 164
Study 7638522 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaraná
Number of subjects: 30
Study 7638522 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 30
Study 7638522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3128318 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 400 micrograms
Number of subjects: 55
Study 3128318 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 600 micrograms
Number of subjects: 55
Study 3128318 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 800 micrograms
Number of subjects: 55
Study 3128318 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 1000 micrograms
Number of subjects: 55
Study 31402637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (group R)
Number of subjects: 60
Study 31402637 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (group V)
Number of subjects: 60
Study 30260460 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine 6 g/day
Number of subjects: 12
Study 30260460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27392904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin for 6 weeks
Number of subjects: 64
Study 27392904 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 64
Study 25917265 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy with mud-pack and hot pool treatments
Number of subjects: 70
Study 25917265 — intervention group
Group type: COMPARATOR
Intervention: Control (patient education alone)
Number of subjects: 70
Study 23837171 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-Ceramic crowns (MC) with glass-fiber posts (GFPs) and composite cores
Number of subjects: 50
Study 23837171 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Ceramic crowns (AC) with glass-fiber posts (GFPs) and composite cores
Number of subjects: 50
Study 23837171 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact canines)
Number of subjects: 50
Study 21115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 h for 5-14 days
Number of subjects: 702
Study 21115454 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g plus aztreonam 1 g every 12 h for 5-14 days
Number of subjects: 702
Study 21115454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 702
Study 21115454 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus aztreonam
Number of subjects: 702
Study 18222256 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein graft markers
Number of subjects: 1778
Study 16758259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg twice daily for 18 days
Number of subjects: 18
Study 16758259 — intervention group
Group type: COMPARATOR
Intervention: Baseline S‐warfarin AUC(0‐infinity)
Number of subjects: 18
Study 16758259 — intervention group
Group type: COMPARATOR
Intervention: Inhibition period S‐warfarin AUC(0‐infinity)
Number of subjects: 18
Study 14610396 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE in alveolar air (PCE‐Alv)
Number of subjects: 26
Study 14610396 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE in blood (PCE‐B)
Number of subjects: 26
Study 14610396 — intervention group
Group type: EXPERIMENTAL
Intervention: PCE in urine (PCE‐U)
Number of subjects: 26
Study 11080324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐managed intervention for smoking cessation and relapse prevention during hospitalization
Number of subjects: 278
Study 11080324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 278
Study 8966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 ml daily for 12 weeks)
Number of subjects: 37
Study 8966087 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 37
Study 8966087 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 37
Study 7880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA) using a 32‐gauge polyimide microcatheter
Number of subjects: 128
Study 7880657 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (SDSA) with a 24‐gauge x 103‐mm Sprotte spinal needle
Number of subjects: 128
Study 7880657 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (CSA)
Number of subjects: 128
Study 7880657 — intervention group
Group type: COMPARATOR
Intervention: Single-dose spinal anaesthesia (SDSA)
Number of subjects: 128
Study 7880657 — intervention group
Group type: COMPARATOR
Intervention: Continuous spinal anaesthesia (CSA) and Single-dose spinal anaesthesia (SDSA)
Number of subjects: 128
Study 2906764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (OC)
Number of subjects: 341
Study 2906764 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 341
Study 2906764 — intervention group
Group type: COMPARATOR
Intervention: Progestogen-only pill
Number of subjects: 341
Study 2906764 — intervention group
Group type: COMPARATOR
Intervention: Nonhormonal methods
Number of subjects: 341
Study 28703949 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSRT + quetiapine
Number of subjects: 92
Study 28703949 — intervention group
Group type: COMPARATOR
Intervention: IPSRT + placebo
Number of subjects: 92
Study 28703949 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment assignment
Number of subjects: 92
Study 26714490 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel-cleansing preparations satisfaction measure (Domain 1)
Number of subjects: 1211
Study 26719313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income source abstracts
Number of subjects: 899
Study 26719313 — intervention group
Group type: COMPARATOR
Intervention: Low-income source abstracts
Number of subjects: 899
Study 22985998 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behaviour therapy (CBT)
Number of subjects: 44
Study 22985998 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education
Number of subjects: 44
Study 22053621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients without glucose (HD-g(-))
Number of subjects: 87
Study 22053621 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservatively treated CRF patients
Number of subjects: 87
Study 22053621 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients with glucose (HD-g(+))
Number of subjects: 87
Study 22053621 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 87
Study 19463293 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting with TAXUS Liberté
Number of subjects: 0
Study 19463293 — intervention group
Group type: COMPARATOR
Intervention: Pre-dilation
Number of subjects: 0
Study 17111989 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy (DBT)
Number of subjects: 6
Study 17111989 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric treatments (treatment as usual)
Number of subjects: 6
Study 12583870 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (GRA) 1 mg/ml injected into the masseter muscle
Number of subjects: 18
Study 12583870 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injected into the masseter muscle
Number of subjects: 18
Study 10898121 — intervention group
Group type: EXPERIMENTAL
Intervention: Amtolmetin guacyl (600 mg on an empty stomach, once daily for 30 days)
Number of subjects: 99
Study 10898121 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg on a full stomach, once daily for 30 days)
Number of subjects: 99
Study 9238884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.3% triclosan and 2.0% PVM/MA copolymer in a 0.331% NaF/silica (1500 ppm F) base
Number of subjects: 1296
Study 9238884 — intervention group
Group type: COMPARATOR
Intervention: Dentifrice containing 0.331% NaF/silica (1500 ppm F) without triclosan and copolymer
Number of subjects: 1296
Study 1622733 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK (3.0 g orally before surgery, daily or every other day)
Number of subjects: 47
Study 1622733 — intervention group
Group type: COMPARATOR
Intervention: Control (no PSK)
Number of subjects: 47
Study 6694339 — intervention group
Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 300
Study 6694339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin
Number of subjects: 300
Study 31347295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone stereotactic guidance
Number of subjects: 116
Study 31347295 — intervention group
Group type: COMPARATOR
Intervention: Upright tomosynthesis guidance
Number of subjects: 116
Study 29054532 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 99
Study 29054532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 26872703 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based coaching program (fully automated) including education, motivation, exercise guidance, daily text message reminders, and weekly feedback.
Number of subjects: 93
Study 26872703 — intervention group
Group type: COMPARATOR
Intervention: Usual care and advice from practitioner (control group).
Number of subjects: 93
Study 26872703 — intervention group
Group type: COMPARATOR
Intervention: Comparison between intervention and control groups.
Number of subjects: 93
Study 24155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg once daily for 14 days plus etravirine 800 mg twice daily for 21 days (days 8-21)
Number of subjects: 32
Study 24155058 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice daily for 13 days plus etravirine 200 mg twice daily for 8 days (days 6-13)
Number of subjects: 32
Study 22015542 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART treatment (budesonide/formoterol 80/4.5 μg Turbuhaler®, two puffs once daily and extra inhalations as needed)
Number of subjects: 102